http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee Yoonha,Kim Minseung,Oh Kyeongeun,Kang Eungu,Rhie Young-Jun,Lee Jieun,Hong Yong Hee,Shin Young-Lim,Kim Jae Hyun 대한의학회 2022 Journal of Korean medical science Vol.37 No.22
Background: Hospital visitation has become challenging during the coronavirus disease 2019 pandemic because of quarantine measures and fear of infection. Consequently, newly diagnosed patients may present with more severe diseases during the pandemic. The present study analyzed the differences in the initial clinical presentations of newly diagnosed patients with type 1 diabetes (T1D) and type 2 diabetes (T2D), comparing pre-pandemic and pandemic periods. Methods: Newly diagnosed patients with T1D or T2D and aged < 18 years during 2018–2020 were included in the study. Data were collected retrospectively from four academic centers in Gyeonggi-do, South Korea. Initial clinical data were compared between the pre-pandemic (2018–2019) and pandemic (2020) periods. Results: In the pre-pandemic and pandemic periods, 99 patients (41 T1D and 58 T2D patients) and 84 patients (51 T1D and 33 T2D patients) were identified, respectively. During the pandemic, the proportion of diabetic ketoacidosis (DKA) cases increased compared to the pre-pandemic period (21.2% during 2018–2019 vs. 38.1% in 2020; P = 0.012). In the prepandemic and pandemic periods, initial pH was 7.32 ± 0.14 and 7.27 ± 0.15, respectively (P = 0.040), and HbA1c values were 11.18 ± 2.46% and 12.42 ± 2.87%, respectively (P = 0.002). During the pandemic, there was an increased risk of DKA in patients with T1D (odds ratio, 2.42; 95% confidence interval, 1.04–5.62; P = 0.040). Conclusion: During the pandemic, the proportion of DKA in newly diagnosed patients with T1D increased and clinical parameters showed a deteriorating pattern. Increased awareness of pediatric diabetes, especially DKA, could facilitate visit to the hospital for an early diagnosis; thus, reducing the number of DKA cases during the pandemic era.
Manivasagan, Panchanathan,Bharathiraja, Subramaniyan,Santha Moorthy, Madhappan,Oh, Yun-Ok,Song, Kyeongeun,Seo, Hansu,Oh, Junghwan American Chemical Society 2017 ACS APPLIED MATERIALS & INTERFACES Vol.9 No.17
<P>The development of novel photothermal ablation agents as cancer nanotheranostics has received a great deal of attention in-recent decades. Biocompatible fucoidan (Fu) is used as the coating material for gold nanorods (AuNRs) and subsequently conjugated with monoclonal antibodies against epidermal growth factor receptor (anti-EGFR) novel photothermal ablation agents for,cancer nanotheranostics because of their excellent biocompatibility, biodegradability, nontoxicity, water solubility, photostability, ease of Surface modification, strongly enhanced absorption in near-infrared (NIR) regions, target specificity, minimal invasiveness, fast recovery, and prevention. of damage to normal tissues: Anti-EGFRFu-AuNRs have an average particle size of 96.37 +/- 3.73 nm. Under 808 nm NIR laser at 2 W/cm(2) for 5 min, the ternperathre of the solution containing anti-EGFR Fu-AuNRs,(30 mu g/mL) increased by 52.1 degrees C. The anti-EGFR Fu-AuNRs exhibited high efficiency for the ablation of MDA-MB-231 cells in vitro. In viva- photothermal ablation exhibited that tumor tissues fully recovered without recurrence and finally were reconstructed with normal-tissues by-the 808 nm NIER. laser irradiatiOn after injection of anti-EGFR Fu-AuNRs. These results suggest that the anti-BUR Fu-AuNRs would be novel photoablation agents for future cancer nanotheranostics:</P>